Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16791245 | 1.00 | USP30 (0.49) | USP30LMNANPSR1HCAR3ALDH1A1 | |
| SCHEMBL16901716 | 0.97 | HCAR3 (0.47) | USP30LMNANPSR1HCAR3ALDH1A1 | |
| SCHEMBL3094959 | 0.88 | ALDH1A1 (0.55) | LMNANPSR1HCAR3ALDH1A1MAPT | |
| SCHEMBL16895791 | 0.88 | HCAR3 (0.51) | USP30LMNAHCAR3ALDH1A1MAPT | |
| SCHEMBL15575457 | 0.88 | USP30 (0.47) | USP30LMNANPSR1HCAR3ALDH1A1 | |
| SCHEMBL16895794 | 0.88 | HCAR3 (0.51) | USP30LMNAHCAR3ALDH1A1MAPT | |
| SCHEMBL744261 | 0.87 | USP30 (0.54) | USP30LMNAALDH1A1MAPTHDAC4 | |
| SCHEMBL744262 | 0.87 | USP30 (0.54) | USP30LMNAALDH1A1MAPTHDAC4 | |
| SCHEMBL4746977 | 0.86 | LMNA (0.47) | USP30LMNANPSR1ALDH1A1MAPT | |
| SCHEMBL18262168 | 0.86 | HCAR3 (0.54) | LMNANPSR1HCAR3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153899-A1 | PHARMACEUTICAL COMPOSITIONS | NOVARTIS PHARMA AG (CH) | 2018-06-07 | — | — | US | disclosed |
| EP-3257848-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | Novartis AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-2773635-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9440957-B2 | Compounds and compositions for modulating EGFR Activity | NOVARTIS AG (CH) | 2016-09-13 | — | — | US | disclosed |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | EGFR, ERBB2, ERBB3 | USP30 2066/4885LMNA 4467/4885NPSR1 1502/4885 |
| US-20180153899-A1 | PHARMACEUTICAL COMPOSITIONS | NR3C2, PTMS, CYP2C19 | USP30 2254/4885LMNA 2652/4885NPSR1 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.